Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 16,542 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Connective Tissue Disease Clear all

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Breast Cancer
Interventions: T-DM1, Lapatinib, Abraxane; Drug
Lead sponsor: Jenny C. Chang, MD; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alopecia Areata
Interventions: Intralesional Triamcinolone 2.5 mg/ml, Intralesional Triamcinolone 5 mg/ml, Intralesional Triamcinolone 10 mg/ml, Intralesional Saline; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 2
States / cities: Minneapolis, Minnesota • New York, New York

Conditions: Melanoma
Interventions: gp100, R848 gel, MAGE-3; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Juvenile Psoriatic Arthritis
Interventions: Secukinumab; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 11
States / cities: Loma Linda, California • Gainesville, Florida • Chicago, Illinois + 8 more

Conditions: Rheumatoid Arthritis, Degenerative Arthritis, Post Traumatic Arthritis
Interventions: Integra Cadence Total Ankle System; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 9
States / cities: San Francisco, California • Sarasota, Florida • Buffalo, New York + 5 more

Conditions: Breast Cancer
Interventions: Tamoxifen; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 25 Years to 45 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2006
U.S. locations: 6
States / cities: Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 2 more

Conditions: Non-infectious Uveitis
Interventions: AIN457, AIN 457; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 20
States / cities: Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more

Conditions: PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2-low Breast Cancer
Interventions: CGT6297; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 9 more

Conditions: Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Nucleophosmin 1-mutated Acute Myeloid Leukemia
Interventions: Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine, Quizartinib; Drug
Lead sponsor: Kura Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 44
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 36 more

Conditions: Breast Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: University of Southern California; Other
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Head and Neck Cancer, Colorectal Cancer
Interventions: PF-07921585, Sasanlimab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 4 more

Conditions: Melanoma
Interventions: TLPLDC, Placebo; Drug
Lead sponsor: Elios Therapeutics, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 15 more

Conditions: Psoriasis, Plaque-type Psoriasis
Interventions: secukinumab, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 12
States / cities: Birmingham, Alabama • Pasadena, California • Indianapolis, Indiana + 9 more

Conditions: Breast Cancer
Interventions: Soy, Milk; Dietary Supplement
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Rejection in Lung Transplant, Cytokine Production in Bos Post Lung Transplant
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: filgrastim, carboplatin, cyclophosphamide, etoposide, mesna, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Temple University; Other
Eligibility: 15 Years to 60 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2003
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Malignant Melanoma Stage IV
Interventions: DC Vaccine & Cyclophosphamide, DC Vaccine & Placebo; Biological
Lead sponsor: Baylor Research Institute; Other
Eligibility: 21 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer
Interventions: Moderate-Intensity Aerobic Exercise Intervention; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Scar Prevention, Scar Reduction
Interventions: AZX100 Drug Product, Placebo; Drug
Lead sponsor: Capstone Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Austin, Texas

Conditions: Anxiety Disorder, Depression, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: minocycline hydrochloride, placebo, laboratory biomarker analysis, Questionnaire administration; Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Melanoma
Interventions: Ipilimumab, Nivolumab, Tocilizumab; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York

Conditions: Melanoma and Metastatic Colorectal Cancer
Interventions: LGX818; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 5
States / cities: Tampa, Florida • Boston, Massachusetts

Search by objective public record fields.

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer

Intralesional Steroids in the Treatment of Alopecia Areata

Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

Clinical Evaluation of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement (CADENCE)

Tamoxifen-MRI Study

Safety and Efficacy of AIN457 in Noninfectious Uveitis

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

Phase IIB TL + YCWP + DC in Melanoma

Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study

Early Indicators of Chronic Rejection in Lung Transplant

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer

PASSION - P Trial: Ph Adjusted Sulfur-Colloid, Sentinel Initiative ON Pain Trial

Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients

Exercise Program in Cancer and Cognition

A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars

Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma